Latest Headlines

Latest Headlines

Merck takes to Europe with its promising PD-1 cancer drug

Merck is racing to be first on the market among contenders in the PD-1 field of cancer therapy, and the European Medicines Agency has agreed to review its pembrolizumab as a treatment for advanced melanoma.

EU smiles on a key cog in Bristol-Myers' hep C combo

European regulators are recommending approval for Bristol-Myers Squibb's daclatasvir, an hepatitis C-fighting antiviral that plays a key role in the company's planned combo treatment.

Woodford buys $50M Prothena stake, Shire lacks 'British gem' status, French biotechs raise €100M

Welcome to the latest edition of our weekly EuroBiotech Report. We lead this week on news that Neil Woodford's much-discussed fund is starting to take shape, with a $50 million (€36.8 million) investment in Elan-spinoff Prothena among its first batch of positions. And more.

Abbott gets EU go-ahead for implant in aging eyes

Cataracts are big business for Abbott. It's ready to roll out the latest in its line of implantable Tecnis lenses in Europe after recently receiving a CE Mark for the product, which will be used to treat cataract patients who may also have a diminished ability, due to aging, to focus on near objects (presbyopia).

Philips launches image-guided neurology surgical tech in Europe

At the Live Interventional Neuroradiology & Neurosurgery Course in, Paris Philips Healthcare launched a new device for minimally invasive image guided neurological surgeries, such as ischemic stroke or large neck aneurism, the NeuroSuite.

EU looks toward new medical device legislation in 2015

In 2012, an immediate action plan as well as new medical device legislation were proposed in the European Union. This week, the Employment, Social Policy, Health and Consumer Affairs Council of the European Commission declared the action plan a success and issued its vision for upcoming legislative changes.

EU opens €24B fund to biopharma R&D, Cardio3 lands Asian investment, U.K. IPOs heat up

In this week's EuroBiotech report, the European Investment Bank is using some of its €24 billion ($33 billion) fund to back drug development, Parisian biotech Cellectis is setting up shop in the U.S. after striking a deal worth up to $2.8 billion with Pfizer, and more.

India's Lupin ready to spend $1B to bulk up in EU

Earlier this year, Indian generic drugmaker Lupin picked up a Netherlands-based manufacturing specialist to extend its reach in sterile injectable drugs within Europe. The company, however, is not done buying capacity and capabilities throughout the continent.

Tissue Regenix talks up acquisition after recent product launch

British regenerative-medicine company Tissue Regenix told  Bloomberg  that it is an attractive acquisition target given its tax and structural advantages. The small cap recently launched its DermaPure decellularized dermis product in the U.S.

EC probes patent box tax breaks, VBL plans $75M IPO, Selvita bags cash for PhI

In this week's edition of the EuroBiotech Report, the European Commission is investigating the United Kingdom's patent box--which partly motivated Pfizer's pursuit of AstraZeneca--and other tax laws in the region. And more.